Board appointment at K-V Pharmaceutical
This article was originally published in Scrip
K-V Pharmaceutical Company (US) has elected Dr David Sidransky as a new independent member of the board of directors. Dr Sidransky replaces John Sampson, whose resignation from the board was effective upon his appointment. Dr Sidransky is professor of oncology, otolaryngology, cellular and molecular medicine, urology, genetics and pathology at John Hopkins University and Hospital.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.